SCD and Parkinson disease: SCD inhibition has also demonstrated efficacy in a 3K mouse model that recapitulates a number of relevant PD phenotypes, including a reduced T/M ratio, increased insoluble and phosphorylated-serine 129 (pS129) αSyn, proteinase K-resistant αSyn, increased lipid-rich structures, and impairments in motor function that are dopamine-responsive [13, 29].